<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305392</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-105</org_study_id>
    <nct_id>NCT04305392</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment</brief_title>
  <official_title>Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment (Multicenter, Single Dose, Parallel, Open)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate pharmacokinetics, pharmacodynamics and safety of SHR4640 in patients with
      mild, moderate hepatic impairment and normal liver function in phase I clinical study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>72 hours after dosing</time_frame>
    <description>Peak Plasma Concentration (Cmax) will be compared between normal hepatic function patients and mild or moderate hepatic dysfunction patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve from single dosing time extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>72 hours after dosing</time_frame>
    <description>Area under the plasma concentration versus time curve from single dosing time extrapolated to infinity (AUC0-∞) will be compared between normal hepatic function patients and mild or moderate hepatic dysfunction patients</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Normal liver function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive single dose of SHR4640</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive single dose of SHR4640</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive single dose of SHR4640</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640</intervention_name>
    <description>orally SHR4640</description>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Normal liver function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -

        All subjects:

          -  Signing the informed consent forms.

          -  18 years to 65 years (inclusive).

          -  Body mass index should be between 18 and 30 kg/m2 (inclusive).

          -  No medication was used before screening#or stable medication for 4 weeks.

        Normal liver function:

        • Clinical laboratory tests during the screening period were normal or the abnormality has
        no clinical significance.

        Hepatic impaired subjects:

          -  Child-Pugh Classification score clinically determined as mild or moderate hepatic
             impairment.

          -  Liver damage due to primary liver disease.

        Exclusion Criteria:

        -

        All subjects:

        • Subject known or suspected of being sensitive to the study drugs or its ingredient.

        Normal liver function:

          -  Previous history of liver function impairment, or physical examination and laboratory
             examination at screening indicated the presence or possibility of liver function
             impairment.

          -  Hepatitis B surface antigen (HBsAg) positive or Anti-hepatitis C virus (HCV) antibody
             or hepatitis C core antigen positive within 3 months prior to administration.

        Hepatic impaired subjects:

          -  Suspected or diagnosed as liver cancer or with other malignant tumors.

          -  Drug induced liver injury#acute liver injury#liver transplantation history.

          -  Subjects with hepatic failure,or severe complications caused by Hepatocirrhosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

